Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-2280 in Cervical Squamous Intraepithelial Lesions
NCT05502367Phase 2Terminated
- Sponsor
- Antiva Biosciences
- Start
- Sep 2022
- Primary completion
- Oct 2025
- Modality
- Transdermal Patches, Hydrogel Systems, Prodrugs/Conditional Activator Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of ABI-2280 in cervical intraepithelial neoplasia (CIN), sponsored by Antiva Biosciences. Started Sep 2022; status: terminated.
02
Drugs
ABI-2280
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT05502367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05502367.